The efficacy and safety of trazodone plus fluoxetine in the treatment of male depression patients
Chen Jing,Lu Z,Zhang B,Xue Wei,Liu Yilan,Yao Peifen,Ji Jianlin,Huang Xiao,Wang Xueshun,Chen Zhiqing,Lu Xinru,Xu Guoqin,Jin Wenlan
DOI: https://doi.org/10.3969/j.issn.1002-0829.2008.05.011
2008-01-01
Abstract:Objective: To explore the efficacy and safety of trazodone plus fluoxetine in treatment of depression patients. Methods: Sixty depression patients were randomly divided into research group(n=30) and control group(n=30). The patients of research group were treated with trazodone plus fluoxetine while control group with fluoxetine. The study lasted for 8 weeks. Before treatment and at the end of 1st, 2nd, 4th, 8th week after treatment, patients were evaluated with Hamilton rating scale for depression (HAMD), Hamilton anxiety scale (HAMA), Athens insomnia scale (AIS), Arizona sexual experience scale (ASEX), the 5-item version of the international index of erectile dysfunction (IIEF-5). Results:At the end of 8th week after treatment, the total score of HAMD, AIS, ASEX, IIEF-5 of research group was significantly better than control group(P<0.05 or P<0.01). At the end of 8th week after treatment, the remission rate of research group was 86.7%. The remission rate of control group was 66.7%. There was no significant difference between two groups(χ2=3.354,P>0.05). The remission rate, significant improvement rate, improvement rate and non-response rate of the research group was respectively 26.67%, 53.33%, 13.33%, 6.67%. The control group was 6.67%, 43.33%, 20.00%, 30.00%. There was significant difference between two groups(χ2=8.765,P<0.05). There was no significant difference between two groups of side effects. Conclusion:Trazodone plus fluoxetine have good efficacy and safety in treating sexual dysfunction, sleep disorder and depressive syndrome in male depression patients.